Tweet
Connor Clark & Lunn Investment Management Ltd. boosted its stake in Meridian Bioscience, Inc. (NASDAQ:VIVO) by 52.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 68,325 shares of the company's stock after purchasing an additional 23,425 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.16% of Meridian Bioscience worth $1,086,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Meridian Bioscience during the 1st quarter worth $104,000. Piedmont Investment Advisors LLC purchased a new position in shares of Meridian Bioscience during the 2nd quarter worth $157,000. Jane Street Group LLC purchased a new position in shares of Meridian Bioscience during the 4th quarter worth $140,000. Cubist Systematic Strategies LLC purchased a new position in shares of Meridian Bioscience during the 1st quarter worth $187,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Meridian Bioscience during the 1st quarter worth $222,000. 86.85% of the stock is owned by institutional investors and hedge funds. Get Meridian Bioscience alerts:
VIVO opened at $14.95 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.89 and a current ratio of 5.73. Meridian Bioscience, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $17.10. The firm has a market cap of $635.93 million, a P/E ratio of 22.27 and a beta of 0.85.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Tuesday, July 31st. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.01. Meridian Bioscience had a net margin of 11.49% and a return on equity of 16.97%. The company had revenue of $51.74 million for the quarter, compared to analysts' expectations of $52.17 million. During the same quarter in the previous year, the company earned $0.16 EPS. Meridian Bioscience's revenue for the quarter was up 3.2% on a year-over-year basis. equities analysts expect that Meridian Bioscience, Inc. will post 0.7 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, August 20th. Investors of record on Friday, August 10th will be paid a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date is Thursday, August 9th. Meridian Bioscience's dividend payout ratio (DPR) is 74.63%.
Several brokerages have recently weighed in on VIVO. BidaskClub cut shares of Meridian Bioscience from a "hold" rating to a "sell" rating in a research note on Wednesday, August 8th. Zacks Investment Research upgraded shares of Meridian Bioscience from a "hold" rating to a "buy" rating and set a $16.00 target price on the stock in a research note on Tuesday, May 1st. Finally, TheStreet upgraded shares of Meridian Bioscience from a "c+" rating to a "b" rating in a research note on Monday, July 2nd.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Story: Diversification in Your Portfolio
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO). Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter 